Every week, Rinchem shares important articles and topics about chemical and gas logistics, industries we operate in, and the general global supply chain. In this week's review we discuss the delay in tariffs, the positive impact of sustainability, and China's impact on the pharma supply chain.
Keep reading to see this week's hot topics.
This week's stats
100%- the proposed tariff rate on imported semiconductors. Reuters
25%- the estimated amount of active pharmaceutical ingredients (APIs) used in U.S. generic drugs that originate from China. FirstWord Pharma
Exclusive: Trump's semiconductor tariff plan likely delayed, officials say
U.S. officials say that what was expected to be a sweeping new tariff ,around 100%, on imported semiconductors under President Donald Trump’s plan may now be delayed, as the administration reconsidered timing and scope to avoid provoking China and destabilizing supply chains.
Why Sustainability Is Smart Business for the Chemical Industry
The American Chemistry Council argues that sustainability isn’t just a moral or environmental goal for the chemical industry — it’s a core business strategy. By embedding sustainability into operations, companies can cut energy use, reduce emissions, and minimize waste, all while driving innovation, lowering costs, and strengthening resilience. These sustainable practices align with broader national priorities like energy security and supply-chain stability, and they help chemical firms stay competitive and responsive to evolving customer demands. Real-world examples from ACC member companies show sustainability investments in carbon capture, recycling, and workforce development are already creating new market opportunities.
US commission warns China could 'weaponise' chokepoints in pharma supply chain
A recent U.S. Commission report warns that China could “weaponize” its dominance in pharmaceutical supply chains, particularly through its control over active pharmaceutical ingredients (APIs) and key starting materials (KSMs). The report suggests that China’s control poses national security risks, and it calls for U.S. legislation to require drug manufacturers to disclose where and how much of these materials they import. The commission notes that decoupling from Chinese biomanufacturing could take years, underlining how deeply entrenched China is in U.S. pharma supply chains.
Get more articles like this in your inbox
Sign up for our monthly newsletter
Find more articles
Request a Quote
